A Phase I Single Ascending Dose Safety, Pharmacokinetic and Pharmacodynamics Study of SEL-212 in Subjects With Elevated Blood Uric Acid

Trial Profile

A Phase I Single Ascending Dose Safety, Pharmacokinetic and Pharmacodynamics Study of SEL-212 in Subjects With Elevated Blood Uric Acid

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs SEL 212 (Primary) ; Pegadricase; Sirolimus
  • Indications Gout; Hyperuricaemia
  • Focus Adverse reactions
  • Sponsors Selecta Biosciences
  • Most Recent Events

    • 17 Jun 2017 Results assessing initial safety and impact on serum uric acid levels and anti-drug antibodies presented at the 18th Annual Congress of the European League Against Rheumatism.
    • 06 Jun 2017 Data from this trial will be presented at the Annual European Congress of Rheumatology (EULAR 2017), according to a Selecta Biosciences media release.
    • 26 Jan 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top